{'fraction_non_alphanumeric': 0.0513595166163142, 'fraction_numerical': 0.07250755287009064, 'mean_word_length': 4.4021739130434785, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Correlation between Breast Cancer Mucin (BCM) and CA 125 Serum Levels in Patients with Active Ovarian Tumors

In a recent work (1), we observed the existence of high BCM serum levels in patients with active ovarian tumors. This finding led us to investigate a possible correlation between that marker and CA 125 serum levels in this kind of pathology. By means of immunoradiometric assays, we determined the serum levels of BCM-RIA (Abbott Germany) and CAl25 (International CIS, France) in 45 women, aged between 37 and 74 years (average 53.4 years.), with active non germinal ovarian carcinomas. The CA 125 values ranged from 11 to 8249 VimI (684.2 ± 1304.3; median 446), while BCM concentrations were between 2 and 145 V Iml (28.1 ± 31.6; median: 19.2). When we compared the values, we observed the existence of a statistically significant correlation between both markers (p = 0.0000; r: 0.73; BCM = 16.273 + 0.017 CA 125). This strong correlation can help us to explain the high percentage